A Phase II, multi-centre, double-blind, randomised, placebo-controlled, 4-way cross-over, dose-range finding study to evaluate efficacy and safety and tolerability of PSD502 in subjects with premature ejaculation (PE).

Registry ID

EUCTR2008-003650-15

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Plethora Solutions Ltd

Start date

2008-12-29

Completion date

2009-07-13

Last update

2026-08-16

Conditions

• Premature Ejaculation

Summary

To evaluate the effect of 3 different doses (3 mg, 30 mg and 53 mg) of PSD502 on Intra-vaginal Ejaculatory Latency Time (IELT),

Locations

• , , Czechia

Related clinical trials

• Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
• Pelvic Floor Therapies for Lifelong Premature Ejaculation
• The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation
• Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
• Ejaculatory and Orgasmic Dysfunction Registry
• Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients

View on source registry